Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis

The Journal of Pediatrics

Volumn 127, Issue 5, 1995, Pages 711-717

  Lang, Alois B ^a   Schaad, Urs B ^a   Rüdeberg, Anna ^a   Wedgwood, Joanna ^a   Que, John U ^a   Fürer, Emil ^a   Cryz Jr , Stanley J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; VACCINE;

ADOLESCENT; ADULT; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION; INFANT; LIPOPOLYSACCHARIDES; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; VACCINES, CONJUGATE;

EID: 0028862352     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(95)70158-3     Document Type: Article

References (24)

1. Pathogenesis of cystic fibrosis
2. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis
3. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
4. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
5. Managements of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients
6. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity
7. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa infection in cystic fibrosis
8. Nonopsonic antibodies in cystic fibrosis: Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative response
9. Proteins of cystic fibrosis respiratory tract: fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis
10. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients
11. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis
12. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa
13. Long-term study of one hundred five patients with cystic fibrosis
14. Relationship between clinical conditions, radiographic findings and pulmonary function in patients with cystic fibrosis
15. The systematic evaluation of the chest radiograph in cystic fibrosis
16. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans
17. Analyses of affinity distribution within polyclonal populations of antigen-specific antibodies: evaluation of accuracy in population detection using monoclonal antibodies
18. Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay
19. Systematic generation of antigen-specific human monoclonal antibodies with therapeutic activities using active immunization
20. Immune complexes and Pseudomonas aeruginosa antibodies in cystic fibrosis.
21. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypeable strains deficient in lipopolysaccharide O side chains
22. Microbiology of airway disease in patients with cystic fibrosis
23. Prospective controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis: three-year results
24. Early pulmonary inflammation in infants with cystic fibrosis